Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong General Hospital; Guangdong Provincial People's Hospital
• Treatments: Fluvoxamine; Methylphenidate

Criteria

Inclusion Criteria:

• Informed consent

• Met DSM-V criteria

• Y-BOCS ≥ 16

• Course of illness ≥ 1year

• Age range between 18~40 years old

• Junior high school education level above

Exclusion Criteria:

• Any other psychiatric axis-I or axis-II disorders

• History of epileptic seizures or any other neurological disorder

• Any other clinically relevant abnormalities in their medical history or laboratory examinations; alcohol or drug abuser